retatrutide clinical trial results 2024 2025 retatrutide weight loss study Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished VisualAbstract: Retatrutide reduces body weight

How GHK-Cu May Support the Appearance of Hair Though GHK-Cu is not a hair regrowth drug, researchers have explored its potential role in scalp support

Cravings shrink, energy stabilizes, and confidence comes back

Always need MD supervision for NPs

Azdan tedavi seenei de mevcuttur

At the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, where Lilly shared its investor relations materials, Mike Czapar laid out the launch sequence directly

The General Pharmaceutical Council made the point bluntly in its April 2025 statement, warning that non-medicinal, unregulated, unlicensed products like Lemon Bottle have potentially caused serious harm and that pharmacies should not be supplying it as if it were a medicine